Loss of Nuclear ARID-1A Expressions Is Associated with Hormone Receptor Status in Breast Cancers.
ARID1A
Breast cancer
HER2
molecular subtype
Journal
European journal of breast health
ISSN: 2587-0831
Titre abrégé: Eur J Breast Health
Pays: Turkey
ID NLM: 101709357
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
27
01
2019
accepted:
11
02
2019
entrez:
20
4
2019
pubmed:
20
4
2019
medline:
20
4
2019
Statut:
epublish
Résumé
Breast cancer is the most common cancer among women worldwide. Adenine thymine-rich interactive domain 1A (ARIDIA) is a tumor suppressor gene involved in chromatin remodeling and it encodes the ARIDIA protein. Recent studies have shown the loss of ARIDIA protein expression in different carcinomas may have a prognostic significance. In the present study, we aimed to evaluate the interactions between ARIDIA loss and molecular subtypes of breast carcinomas. ARIDIA expressions were studied in 292 formalin- fixed, paraffin- embedded breast carcinoma specimens and its association with different pathological and clinical parameters was evaluated. Loss of ARIDIA expression was detected in 123 cases. There was no statistically significant association between ARID-1A expression and molecular subtype of breast carcinomas (p=0.110) or HER2 amplification (p=0.909). Contrarily, there was a significant association between ARIDIA expression and presence of estrogen (p=0.047) or progesterone receptors (p=0.023). Besides a statistically significant relationship was found between loss of ARID1A, and the presence of both in situ component (p=0.016) and lymph node metastasis (p=0.001). In this study, we have demonstrated that loss of ARID1A expression positively correlates with hormone receptor status as well as tumor aggressiveness.
Identifiants
pubmed: 31001615
doi: 10.5152/ejbh.2019.4677
pii: ejbh-15-2-125
pmc: PMC6456276
doi:
Types de publication
Journal Article
Langues
eng
Pagination
125-129Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no conflicts of interest to declare.
Références
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Am J Surg. 2003 Feb;185(2):165-7
pubmed: 12559449
N Engl J Med. 2003 Jun 5;348(23):2339-47
pubmed: 12788999
Mod Pathol. 2004 Jun;17(6):646-52
pubmed: 15073596
Mod Pathol. 2005 Jan;18(1):26-35
pubmed: 15332092
Oncogene. 2007 Oct 4;26(45):6469-87
pubmed: 17471238
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Breast Cancer Res Treat. 2010 Jan;119(1):119-26
pubmed: 19669409
Breast Cancer Res. 2011;13(6):221
pubmed: 22217398
Gene Expr. 2011;15(3):105-15
pubmed: 22268293
Cancer Epidemiol. 2012 Jun;36(3):237-48
pubmed: 22459198
PLoS One. 2012;7(7):e40364
pubmed: 22808142
Mod Pathol. 2014 Feb;27(2):255-61
pubmed: 23887303
Breast. 2013 Aug;22 Suppl 2:S12-8
pubmed: 24011769
Tumour Biol. 2014 May;35(5):4813-9
pubmed: 24430365
Hum Pathol. 2014 Jun;45(6):1258-68
pubmed: 24767857
World J Clin Oncol. 2014 Aug 10;5(3):412-24
pubmed: 25114856
J Natl Cancer Inst. 2014 Aug 12;106(8):null
pubmed: 25118203
APMIS. 2015 Oct;123(10):847-50
pubmed: 26303865
Oncol Rep. 2016 Feb;35(2):607-13
pubmed: 26572704
Indian J Pathol Microbiol. 2018 Jul-Sep;61(3):323-329
pubmed: 30004048